X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (26569) 26569
Book Review (4958) 4958
Publication (2091) 2091
Conference Proceeding (214) 214
Book Chapter (185) 185
Newspaper Article (33) 33
Magazine Article (16) 16
Web Resource (11) 11
Dissertation (10) 10
Trade Publication Article (9) 9
Book / eBook (2) 2
Reference (2) 2
Data Set (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
rituximab (22728) 22728
humans (18546) 18546
index medicus (18140) 18140
female (9657) 9657
male (9463) 9463
middle aged (7875) 7875
adult (6626) 6626
aged (6178) 6178
hematology (6155) 6155
oncology (5938) 5938
treatment outcome (5409) 5409
antibodies, monoclonal, murine-derived (5141) 5141
antibodies, monoclonal - therapeutic use (4241) 4241
therapy (4104) 4104
antineoplastic combined chemotherapy protocols - therapeutic use (3545) 3545
chemotherapy (3339) 3339
non-hodgkins-lymphoma (2972) 2972
antibodies, monoclonal, murine-derived - therapeutic use (2912) 2912
lymphomas (2886) 2886
lymphoma (2712) 2712
cancer (2560) 2560
antineoplastic agents - therapeutic use (2549) 2549
prognosis (2487) 2487
aged, 80 and over (2485) 2485
care and treatment (2394) 2394
transplantation (2311) 2311
cyclophosphamide (2277) 2277
rheumatology (2249) 2249
immunology (2202) 2202
retrospective studies (2191) 2191
immunologic factors - therapeutic use (2039) 2039
abridged index medicus (2030) 2030
b-cell lymphoma (1952) 1952
adolescent (1936) 1936
young adult (1912) 1912
medicine & public health (1814) 1814
antibodies, monoclonal - administration & dosage (1796) 1796
rituximab - therapeutic use (1730) 1730
immunosuppressive agents - therapeutic use (1728) 1728
antibodies, monoclonal, murine-derived - administration & dosage (1716) 1716
survival (1694) 1694
cyclophosphamide - administration & dosage (1678) 1678
lymphoma, large b-cell, diffuse - drug therapy (1622) 1622
patients (1622) 1622
immunotherapy (1567) 1567
disease (1564) 1564
trial (1529) 1529
animals (1520) 1520
remission induction (1504) 1504
recurrence (1486) 1486
medicine, general & internal (1452) 1452
risk factors (1452) 1452
disease-free survival (1449) 1449
analysis (1415) 1415
follow-up studies (1391) 1391
efficacy (1373) 1373
antineoplastic combined chemotherapy protocols - administration & dosage (1370) 1370
chronic lymphocytic-leukemia (1370) 1370
drug therapy (1369) 1369
monoclonal antibodies (1299) 1299
follicular lymphoma (1297) 1297
research (1287) 1287
rheumatoid arthritis (1286) 1286
diagnosis (1267) 1267
vincristine - administration & dosage (1262) 1262
anti-cd20 monoclonal-antibody (1261) 1261
health aspects (1254) 1254
hemic and lymphatic diseases (1231) 1231
cyclophosphamide - therapeutic use (1197) 1197
doxorubicin - administration & dosage (1194) 1194
child (1190) 1190
antibodies (1138) 1138
b-lymphocytes - immunology (1128) 1128
antibodies, monoclonal - adverse effects (1127) 1127
prednisone - administration & dosage (1104) 1104
antineoplastic agents (1073) 1073
leukemia, lymphocytic, chronic, b-cell - drug therapy (1065) 1065
time factors (1047) 1047
pharmacology & pharmacy (1032) 1032
antigens, cd20 - immunology (1027) 1027
antimitotic agents (1013) 1013
combined modality therapy (1011) 1011
antirheumatic agents - therapeutic use (1007) 1007
lymphocytes b (1006) 1006
elderly-patients (977) 977
antineoplastic combined chemotherapy protocols - adverse effects (971) 971
drug therapy, combination (969) 969
lymphoma, b-cell - drug therapy (968) 968
antibodies, monoclonal, murine-derived - adverse effects (956) 956
expression (946) 946
lymphoma, large b-cell, diffuse - pathology (943) 943
rituximab - administration & dosage (936) 936
lymphoma, non-hodgkin - drug therapy (935) 935
rheumatoid-arthritis (926) 926
safety (921) 921
surgery (918) 918
fludarabine (892) 892
survival analysis (884) 884
article (865) 865
immune system diseases (865) 865
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (24021) 24021
French (608) 608
German (522) 522
Spanish (412) 412
Japanese (407) 407
Chinese (197) 197
Russian (175) 175
Korean (97) 97
Polish (96) 96
Czech (74) 74
Hungarian (54) 54
Portuguese (50) 50
Italian (43) 43
Turkish (24) 24
Danish (16) 16
Croatian (13) 13
Dutch (10) 10
Hebrew (9) 9
Finnish (7) 7
Norwegian (6) 6
Serbian (6) 6
Slovenian (6) 6
Slovak (5) 5
Swedish (3) 3
Icelandic (2) 2
Indonesian (2) 2
Persian (2) 2
Romanian (2) 2
Arabic (1) 1
Bosnian (1) 1
Catalan (1) 1
Estonian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Rheumatology, ISSN 1462-0324, 04/2018, Volume 57, Issue suppl_3
Journal Article
Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, 07/2017, Volume 15, Issue 7, p. 729
Journal Article
Hematological Oncology, ISSN 0278-0232, 06/2017, Volume 35, Issue S2, pp. 271 - 272
Journal Article
British Journal of Haematology, ISSN 0007-1048, 12/2015, Volume 171, Issue 5, pp. 763 - 775
Obinutuzumab is a novel glycoengineered Type‐ II CD 20 monoclonal antibody. CD 20 is expressed in approximately 100% of children and adolescents with Burkitt... 
ALL | pre‐B | BL | rituximab‐sensitive | rituximab‐resistant | obinutuzumab | rituximab | Rituximab | Obinutuzumab | Pre-B-ALL | Rituximab-sensitive BL | Rituximab-resistant BL | pre-B-ALL | NATURAL-KILLER-CELLS | ONCOLOGY GROUP-REPORT | rituximab-sensitive BL | rituximab-resistant ill | PHASE I/II | CHEMOTHERAPY PLUS RITUXIMAB | CHILDREN | IN-VITRO | ANTI-CD20 MONOCLONAL-ANTIBODY | NON-HODGKIN-LYMPHOMA | CHRONIC LYMPHOCYTIC-LEUKEMIA | RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA | HEMATOLOGY | Neoplasm Transplantation | Apoptosis - drug effects | Humans | Transplantation, Heterologous | Rituximab - pharmacology | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Animals | Caspases - metabolism | Antibodies, Monoclonal, Humanized - pharmacology | Survival Analysis | Cell Line, Tumor | Caspases - drug effects | Lysosomal-Associated Membrane Protein 1 - metabolism | Antineoplastic Agents - pharmacology | Cell Proliferation - drug effects | Killer Cells, Natural - drug effects | Mice | Interferon-gamma - biosynthesis | Molecular Targeted Therapy - methods | Burkitt Lymphoma - drug therapy | Disease Models, Animal | Drug Resistance, Neoplasm - drug effects | Antimitotic agents | Evaluation | Cell death | Patient outcomes | Monoclonal antibodies | Biochemistry | Comparative analysis | Antineoplastic agents | Burkitt's lymphoma | Index Medicus
Journal Article
WHO Drug Information, ISSN 1010-9609, 04/2017, Volume 31, Issue 2, p. 190
Journal Article
Blood, ISSN 0006-4971, 05/2019, Volume 133, Issue 19, pp. 2003 - 2004
In this issue of Blood, Byrd et al report that after nearly 4 years of follow-up, there is an impressive and sustained progression-free survival and overall... 
HEMATOLOGY | RITUXIMAB
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 03/2019, Volume 37, Issue 9, pp. 759 - 759
Journal Article
JAMA, ISSN 0098-7484, 11/2017, Volume 318, Issue 17, pp. 1717 - 1717
A poem is presented. 
Rituximab | Poetry
Journal Article
Rheumatology, ISSN 1462-0324, 04/2018, Volume 57, Issue suppl_3
Journal Article
British Journal of Haematology, ISSN 0007-1048, 11/2017, Volume 179, Issue 3, pp. 410 - 420
Male sex is associated with unfavourable pharmacokinetics and prognosis in elderly patients with diffuse large B‐cell lymphoma ( DLBCL ). We investigated... 
diffuse large B‐cell lymphoma | rituximab dose | sex | rituximab pharmacokinetics | diffuse large B-cell lymphoma | DSHNHL | RANDOMIZED CONTROLLED-TRIAL | PHASE-3 | CHEMOTHERAPY PLUS RITUXIMAB | TRANSPLANTATION | ACUTE HEMATOLOGICAL TOXICITY | MAINTENANCE | B-CELL LYMPHOMA | NON-HODGKINS-LYMPHOMA | CHOP | HEMATOLOGY | Doxorubicin - blood | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Antineoplastic Combined Chemotherapy Protocols - blood | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Rituximab - blood | Vincristine - blood | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Dose-Response Relationship, Drug | Aged, 80 and over | Vincristine - administration & dosage | Female | Doxorubicin - administration & dosage | Rituximab - adverse effects | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Lymphoma, Large B-Cell, Diffuse - pathology | Treatment Outcome | Prednisone - blood | Rituximab - administration & dosage | Cyclophosphamide - blood | Medication Adherence | Lymphoma, Large B-Cell, Diffuse - blood | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Sex Factors | Survival Analysis | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Neoplasm Staging | Doxorubicin - adverse effects | Prednisone - therapeutic use | Aged patients | Care and treatment | Anthracyclines | Lymphomas | Corticosteroids | Analysis | Elderly people | Drugs | Toxicity | Sex | Males | Doxorubicin | Optimization | Risk factors | Rituximab | Pharmacology | Prednisone | Risk analysis | Survival | Patients | Vincristine | Lymphoma | Serum levels | Cyclophosphamide | Lymphocytes B | Medical prognosis | Females | Pharmacokinetics | Elderly | Geriatrics | B-cell lymphoma | Index Medicus
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2018, Volume 378, Issue 12, pp. 1107 - 1120
In a trial involving patients with relapsed or refractory chronic lymphocytic leukemia, the BCL2 inhibitor venetoclax in combination with rituximab resulted in... 
SURVIVAL | TRIAL | MEDICINE, GENERAL & INTERNAL | INDEPENDENT PREDICTOR | 17P DELETION | TARGETING BCL2 | PLUS RITUXIMAB | TP53 MUTATION | PROGRESSION-FREE | OPEN-LABEL | MINIMAL RESIDUAL DISEASE | Recurrence | Bendamustine Hydrochloride - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Male | Neoplasm, Residual | Young Adult | Bendamustine Hydrochloride - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Tumor Lysis Syndrome - etiology | Aged, 80 and over | Adult | Female | Neutropenia - chemically induced | Rituximab - adverse effects | Kaplan-Meier Estimate | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Sulfonamides - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Sulfonamides - administration & dosage | Treatment outcome | Chronic lymphocytic leukemia | Diagnosis | Analysis | Chronic lymphatic leukemia | Cell survival | Hematology | Leukemia | Rituximab | Clinical trials | Oncology | Chromosome deletion | Lymphatic leukemia | Patients | Cancer therapies | Chemotherapy | Clonal deletion | Lysis | Response rates | Bone marrow | Chromosomes | Drug dosages | Chromosome 17 | Neutropenia | Index Medicus | Abridged Index Medicus | Life Sciences | Cancer
Journal Article
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, 03/2019, Volume 17, Issue 3, pp. 330 - 332
Journal Article
Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, 07/2018, Volume 16, Issue 7, pp. 897 - 900
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 08/2016, Volume 75, Issue 8, pp. 1576 - 1578
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.